Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
More News related to ABMD
- Abiomed to Present at the 21st Annual Piper Jaffray Healthcare Conference
- Lazard Capital Downgrades Abiomed (ABMD) to Hold
- Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
- Abiomed Announces Record Revenue of $20 Million for Second Quarter of Fiscal 2010
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Earnings
- Shields & Co. Downgrades ALLETE, Inc. (ALE) to Hold
- Scotia Capital Downgrades Grupo Aeroportuario del Centro (OMAB) to Sector Perform
- Goldman Sachs Upgrades Bradesco and Banco do Brasil; Downgrades Bancolombia
- Wedbush Downgrades Burger King (BKC) to Underperform
- Morgan Stanley Upgrades Safeway (SWY), Downgrades SUPERVALU (SVU)
Abiomed, Inc. (NASDAQ: ABMD) reports Q2 loss of $0.21, even with the analyst estimate of ($0.21). Revenue for the quarter was $20.02 million, which compares to the estimate of $20.14 million.
Related Categories
EarningsStocks Mentioned
-0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
